Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Schmid

Showing results (71-80 of 95) with videos related to

Pageof 10
Sort By:
Scientific Reports|July 8, 2023
Synthesis and pharmacological activity of the epimers of hexahydrocannabinol (HHC)Fabiana Russo, Maria Angela Vandelli, Giuseppe Biagini, et al.
The Journal of Allergy and Clinical Immunology. in Practice|October 13, 2023
Tobacco Exposure and Efficacy of Biologic Therapy in Patients With Severe Asthma: A Nationwide Study From the Danish Severe Asthma RegisterMarianne Baastrup Soendergaard, Susanne Hansen, Anne-Sofie Bjerrum, et al.
ERJ Open Research|March 18, 2026
Cumulative corticosteroid burden over 25 years in patients initiating biologic therapy for severe asthma: a nationwide cohort studyGalathea Berner, Marianne Baastrup Soendergaard, Susanne Hansen, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 5, 2026
Five-year inhaled, systemic and total corticosteroid exposure reduction during anti-Interleukin-5/Rα treatment for severe asthmaKjell Erik Julius Håkansson, Susanne Hansen, Marianne Baastrup Soendergaard, et al.
Allergy|December 14, 2024
Early Reduction of FeNO on Anti-IL5 Biologics Is Associated With Clinical Remission of Severe AsthmaMarianne Baastrup Soendergaard, Susanne Hansen, Kjell Erik Julius Håkansson, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|July 15, 2025
Biologic Prescription Patterns and Biomarker Determinants of First-Line Dupilumab in Danish Adult Patients With Severe Asthma and Comorbid Atopic DermatitisMarianne Baastrup Soendergaard, Kjell Erik Julius Håkansson, Susanne Hansen, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 13, 2025
Tezepelumab in Real-Life Practice: Characteristics of Patients Commenced and Efficacy in a Nationwide, Danish Cohort of Patients With Severe AsthmaMarianne Baastrup Soendergaard, Kjell Erik Julius Haakansson, Susanne Hansen, et al.
Lung|March 12, 2025
Supratherapeutic Inhaled Corticosteroid Use in Patients Initiating on Biologic Therapies for Severe Asthma: A Nationwide Cohort StudyFrederikke Hjortdahl, Marianne Baastrup Soendergaard, Susanne Hansen, et al.
The European Respiratory Journal|January 9, 2025
Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthmaMarianne Baastrup Soendergaard, Frederikke Hjortdahl, Susanne Hansen, et al.
ERJ Open Research|October 6, 2022
Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma RegisterMarianne Baastrup Soendergaard, Susanne Hansen, Anne-Sofie Bjerrum, et al.
Pageof 10

Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Scientific Reports|July 8, 2023
Synthesis and pharmacological activity of the epimers of hexahydrocannabinol (HHC)Fabiana Russo, Maria Angela Vandelli, Giuseppe Biagini, et al.
The Journal of Allergy and Clinical Immunology. in Practice|October 13, 2023
Tobacco Exposure and Efficacy of Biologic Therapy in Patients With Severe Asthma: A Nationwide Study From the Danish Severe Asthma RegisterMarianne Baastrup Soendergaard, Susanne Hansen, Anne-Sofie Bjerrum, et al.
ERJ Open Research|March 18, 2026
Cumulative corticosteroid burden over 25 years in patients initiating biologic therapy for severe asthma: a nationwide cohort studyGalathea Berner, Marianne Baastrup Soendergaard, Susanne Hansen, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 5, 2026
Five-year inhaled, systemic and total corticosteroid exposure reduction during anti-Interleukin-5/Rα treatment for severe asthmaKjell Erik Julius Håkansson, Susanne Hansen, Marianne Baastrup Soendergaard, et al.
Allergy|December 14, 2024
Early Reduction of FeNO on Anti-IL5 Biologics Is Associated With Clinical Remission of Severe AsthmaMarianne Baastrup Soendergaard, Susanne Hansen, Kjell Erik Julius Håkansson, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|July 15, 2025
Biologic Prescription Patterns and Biomarker Determinants of First-Line Dupilumab in Danish Adult Patients With Severe Asthma and Comorbid Atopic DermatitisMarianne Baastrup Soendergaard, Kjell Erik Julius Håkansson, Susanne Hansen, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 13, 2025
Tezepelumab in Real-Life Practice: Characteristics of Patients Commenced and Efficacy in a Nationwide, Danish Cohort of Patients With Severe AsthmaMarianne Baastrup Soendergaard, Kjell Erik Julius Haakansson, Susanne Hansen, et al.
Lung|March 12, 2025
Supratherapeutic Inhaled Corticosteroid Use in Patients Initiating on Biologic Therapies for Severe Asthma: A Nationwide Cohort StudyFrederikke Hjortdahl, Marianne Baastrup Soendergaard, Susanne Hansen, et al.
The European Respiratory Journal|January 9, 2025
Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthmaMarianne Baastrup Soendergaard, Frederikke Hjortdahl, Susanne Hansen, et al.
ERJ Open Research|October 6, 2022
Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma RegisterMarianne Baastrup Soendergaard, Susanne Hansen, Anne-Sofie Bjerrum, et al.
Pageof 10